Non-human primate pluripotent stem cells for the preclinical testing of regenerative therapies
Ignacio Rodríguez-Polo
Rüdiger Behr
Research Platform Degenerative Diseases,German Primate Center-Leibniz Institute for Primate Research,G(o)ttingen,Germany;German Center for Cardiovascular Research (DZHK),Partner Site G(o)ttingen,G(o)ttingen,Germany
摘要：Non-human primates play a key role in the preclinical validation of pluripotent stem cell-based cell replacement therapies.Pluripotent stem cells used as advanced therapy medical products boost the possibility to regenerate tissues and organs affected by degenerative diseases.Therefore,the methods to derive human induced pluripotent stem cell and embryonic stem cell lines following clinical standards have quickly developed in the last 15 years.For the preclinical validation of cell replacement therapies in non-human primates,it is necessary to generate non-human primate pluripotent stem cell with a homologous quality to their human counterparts.However,pluripotent stem cell technologies have developed at a slower pace in non-human primates in comparison with human cell systems.In recent years,however,relevant progress has also been made with non-human primate pluripotent stem cells.This review provides a systematic overview of the progress and remaining challenges for the generation of non-human primate induced pluripotent stem cells/embryonic stem cells for the preclinical testing and validation of cell replacement therapies.We focus on the critical domains of (1) reprogramming and embryonic stem cell line derivation,(2) cell line maintenance and characterization and,(3) application of non-human primate pluripotent stem cells in the context of selected preclinical studies to treat cardiovascular and neurodegenerative disorders performed in non-human primates.
机标关键词：
论文发表日期：2022-09-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：8( 1867-1874 )
英文信息